S. Yasuda, A. Ohnisi, T. Ogawa, Y. Tomono, J. Hasegawa, H. Nakai, Y. Shimamura and N. Morishita, “Pharmacokinetic Properties of E3810, a New Proton Pump Inhibitor, in Healthy Male Volunteers,” International Journal of Clinical Pharmacology and Therapeutics, Vol. 32, No. 9, 1994, pp. 466-473.

has been cited by the following article:

• TITLE: Influence of the Meal and Genotype of CYP2C19 on the Pharmacokinetics of Proton Pump Inhibitors in Healthy Japanese Subjects

  AUTHORS: Hirohiko Shinkai, Tomoyuki Koike, Miki Shimada, Kenichiro Nakagawa, Katsunori Iijima, Yotaro Matsumoto, Masamitsu Maekawa, Nariyasu Mano, Tooru Shimosegawa

  KEYWORDS: Proton Pump Inhibitor; Omeprazole; Rabeprazole; CYP2C19; Pharmacokinetics

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.6, September 16, 2013

  ABSTRACT: Objectives: To evaluate the influence of meals on the pharmacokinetics of omeprazole and rabeprazole and to investigate these PPIs with reference to CYP2C19 genotypes in healthy Japanese men. Methods: This was a randomized, open label, four-way crossover study. Twelve healthy Japanese male volunteers received a single oral dose of either 20 mg omeprazole or 10 mg rabeprazole, in the fasted state and after a standardized breakfast. Results: Between the administration of omeprazole in the fasted state and after breakfast, there were no significant differences in Cmax, AUC, Tmax, and half-life. Between the administration of rabeprazole in the fasted state and after breakfast, there were no significant differences in Cmax, AUC and half-life, whereas the Tmax of rabeprazole after breakfast was significantly delayed (2.8 ± 1.0 vs 5.3 ± 1.8 h, respectively; p = 0.006). PMs demonstrated the highest Cmax and AUC after drug intake under the fasting state and after breakfast, and homo EMs showed a significantly delayed Tmax. Conclusion: When a single dose of either PPI was administered, the pharmacokinetics of omeprazole was not affected by the meal, whereas the Tmax of rabeprazole after the meal was significantly delayed.